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Abstract: Resistant hypertension, defined as failure to achieve target blood pressure despite 
the use of optimal or maximum doses of at least 3 agents, one of which is a diuretic, or 
requiring 4 or more medications to achieve blood pressure goal, is likely to affect up to 
20% of all patients with hypertension. Apparent resistant hypertension may be caused by 
medication nonadherence, substances that either interfere with antihypertensive media-
tions or cause blood pressure elevation, and under- or inappropriate medication treatment. 
Certain patient characteristics are associated with the presence of resistant hypertension 
and include chronic kidney disease, diabetes, obesity, and presence of end-organ damage 
(microalbuminuria, retinopathy, left-ventricular hypertrophy). Secondary causes of resis-
tant hypertension are not uncommon and include obstructive sleep apnea, chronic kidney 
disease, primary aldosteronism, renal artery stenosis, pheochromocytoma, and Cushing’s 
disease. Initial medication management usually includes adding or increasing the dose of 
a diuretic, which is effective in lowering the blood pressure of a large number of patients 
with resistant hypertension. Additional management options include maximizing lifestyle 
modification, combination therapy of antihypertensive agents depending on individual patient 
characteristics, adding less-commonly used fourth- or fifth-line antihypertensive agents, and 
referral to a hypertension specialist.
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Introduction
Resistant hypertension (RH) is defined as blood pressure that is above the patient’s 
goal despite the use of 3 or more antihypertensive agents from different classes (one 
of which should ideally be a diuretic) at optimal doses.1 This definition includes people 
who require 4 or more medications to achieve blood pressure control. Resistant hyper-
tension is distinguished from uncontrolled hypertension. Uncontrolled hypertension 
includes both patients with inadequately treated hypertension and those with true 
resistant hypertension.1,2 It is usually more difficult to attain systolic blood pressure 
goals than diastolic blood pressure goals.1
Patients with resistant hypertension are at higher risk for end-organ damage such as 
left ventricular hypertrophy, atherosclerotic plaques, retinopathy, and microalbuminuria 
than similar patients who have controlled hypertension3,4 making both identification of 
and treatment of patients with RH important in prevention of cardiovascular morbidity 
and mortality. Additionally, patients with true resistant hypertension are at increased 
risk for cardiovascular morbidity and mortality compared with hypertensive patients 
with controlled hypertension or pseudoresistance.5Integrated Blood Pressure Control 2009:1 10
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Incidence/prevalence
The exact prevalence of resistant hypertension is unknown1 
but has been estimated to be 10% to 20%.6–8 Patient charac-
teristics associated with resistant hypertension include older 
age, higher baseline systolic blood pressure, obesity, excessive 
salt consumption, chronic kidney disease, diabetes, left ven-
tricular hypertrophy, black race, female gender, and living in 
the southeastern United States.1,8 Certain genetic phenotypes 
may also promote the development of resistant hypertension, 
although this area of study is relatively limited.1
Pseudoresistance
Pseudoresistance is uncontrolled hypertension caused by 
under treatment or treatment with inappropriate agents, incor-
rect blood pressure measurement, white coat hypertension, 
or medication nonadherence.9 Differentiating true resistant 
hypertension from pseudoresistance is a key component 
of patient evaluation.1,3,10 This includes: identification of 
substances that may contribute to or cause elevated blood 
pressure, identification of secondary causes, evaluation of 
medication adherence, and establishing correct blood pres-
sure measurement. Two common causes of incorrect blood 
pressure measurement are not allowing the patient to sit 
quietly before obtaining the measurement and using a cuff 
that is too small.1
Since up to 30% of patients with apparent resistant hyper-
tension may evidence blood pressure control on 24-hour 
ambulatory blood pressure monitoring (ABPM), using 
24-hour ABPM is indicated in establishing the diagnosis of 
true resistant hypertension.9,11,12 White coat hypertension may 
mimic resistant hypertension, and one study found a 20% to 
30% prevalence of controlled blood pressure as measured 
by 24-hour ambulatory blood pressure monitoring among 
patients with resistant hypertension.11 White coat hyperten-
sion or pseudoresistance should be considered in patients with 
apparent resistant hypertension who do not have evidence of 
end-organ damage or who have symptoms of hypotension.13,14 
In elderly patients, arterial stiffness may cause pseudoresis-
tance because less compressible stiff arteries cause falsely 
elevated blood pressure readings.15
In distinguishing patients with true resistant hypertension 
from patients with white coat hypertension, certain patient 
characteristics show a higher likelihood of being associ-
ated with true resistant hypertension. These characteristics 
include: male gender, systolic blood pressure in the office 
of 180 mmHg, elevated fasting blood sugar, low serum 
potassium, and evidence of end-organ disease (microalbu-
minuria, left ventricular hypertrophy).16
Factors associated with resistant 
hypertension
Obesity is associated with an increased risk of resistant 
hypertension and higher blood pressure readings in general.1 
While the reasons for the increased risk of resistant hyperten-
sion in obese patients is not known with certainty, factors 
hypothesized to play a role include sympathetic activation 
in the kidney, increased activation of the renin-angiotensin 
system, increased intrarenal pressures from surrounding 
adipose tissue, and changes to the renal architecture includ-
ing glomerular injury.17
Diabetes and hypertension are closely associated, 
although the role of insulin resistance in causing hypertension 
is not defined.1 Patients with both diabetes and hyperten-
sion are more likely to have uncontrolled hypertension and 
typically require 2 or more antihypertensive agents to reach 
blood pressure goals.1,2
Ingestion of salt in the diet is associated with both essen-
tial hypertension and resistant hypertension. Older patients, 
African-American patients, and patients with chronic kidney 
disease may be particularly susceptible to the blood pressure 
effects of salt intake.1
Excessive alcohol consumption as well as use of illicit 
drugs can be associated with resistant hypertension.1 
Cigarette smoking can elevate blood pressure for up to 30 
minutes and should be considered a potential cause of an 
elevated blood pressure reading.18
Medications, both over-the-counter and prescription, 
can cause elevated blood pressure and may play a role in 
resistant hypertension (see Table 1). Common medications 
that can cause elevated blood pressure include: nonsteroidal 
anti-inflammatory medications, aspirin, COX-2 inhibitors, 
decongestants, stimulant medications used for weight loss, 
narcolepsy or attention deficit disorder, oral contraceptive 
pills, cyclosporine, and erythropoieitin.1 Herbal supplements 
that act as stimulants such as ma huang or ephedra also can 
cause elevated blood pressure.
Secondary causes of resistant hypertension include 
obstructive sleep apnea, chronic kidney disease, primary 
aldosteronism, renal artery stenosis, pheochromocytoma, 
Cushing’s disease, coarctation of the aorta, hyper- or hypo-
thyroidism, and intracranial tumor1,3 and are present in 
approximately 10% to 20% of patients with resistant hyper-
tension who are adherent with prescribed treatment.19
Obstructive sleep apnea
Obstructive sleep apnea (OSA) is independently associated 
with resistant hypertension with a reported odds ratio of 5.0 in Integrated Blood Pressure Control 2009:1 11
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one case control study20 and has been reported to be present in 
the majority of patients with resistant hypertension presenting 
to a hypertension clinic.21 Increased severity of OSA is associ-
ated with increased risk for resistant hypertension.1,2
In a group of patients with resistant hypertension, those 
with a higher probability of having OSA had a significantly 
higher prevalence of primary aldosteronism (PA) compared 
to those with a lower probability of OSA based on a validated 
questionnaire (36 vs 19%).22 A study of consecutive patients 
with resistant hypertension found a relationship between 
severity of obstructive sleep apnea and aldosterone excess.21 
This may indicate that obstructive sleep apnea stimulates 
aldosterone excretion leading to an increased risk of PA and 
therefore RH in patients affected by OSA. Alternatively, 
another factor such as obesity may increase risk for both OSA 
and excess aldosterone excretion.22 Hypoxia experienced by 
patients with OSA likely leads to sympathetic nervous system 
activation which in turn raises blood pressure.1
Treatment of OSA with a continuous positive airway 
pressure (CPAP) device has been shown to reduce blood 
pressure levels, with the greatest benefit seen in those with 
severe OSA who were already receiving antihypertensive 
treatment.1
Primary aldosteronism
Approximately 10% to 20% of patients with resistant 
hypertension have primary aldosteronism (PA).1,23 The preva-
lence of PA tends to increase with increasingly severe hyperten-
sion.24 PA may be associated with both obesity and OSA.1
Aldosterone has been demonstrated to exert a number of 
influences leading to increased systemic vascular resistance 
including an association with endothelial dysfunction, vascular 
remodeling through collagen deposition, vascular damage, 
impairment of the baroreflex leading to loss of compensation 
for elevated blood pressure, and hypervolemia.2,24,25 Aldoste-
rone may promote both renal and cardiovascular injury by 
mechanisms other than blood pressure elevation.24 Aldosterone 
excess, in the absence of diagnosed primary aldosteronism, 
may contribute to resistant hypertension as evidenced by the 
benefit of aldosterone antagonists in patients both with and 
without PA as well as the demonstration of biochemical mark-
ers of aldosterone excess in patients with RH.8 Primary aldoste-
ronism may represent the end-point of a continuum that starts 
with a low-renin, normotensive state and progresses through 
low-renin hypertension to normokalemic primary aldosteron-
ism and finally hypokalemic primary aldosteronism.26,27
Primary aldosteronism may be suggested by hypokalemia,7 
although this may be a late finding of the disease process, 
occurring after hypertension has already developed.1 PA 
is equally prevalent among both black and white patients 
with RH.7
Since primary aldosteronism is often effectively treated 
with an aldosterone antagonist, it remains controversial 
whether establishing the diagnosis is necessary in those 
patients who screen positive with an elevated aldosterone-
renin ratio.28,29 While adrenal adenectomy is indicated when 
an aldosterone-producing adenoma is found and can be 
curative of primary aldosteronism and hypertension, most 
patients found to have primary aldosteronism do not have an 
identified adenoma and can be medically managed.28
Chronic kidney disease
Multiple factors likely cause hypertension in patients with 
chronic kidney disease. These include intravascular volume 
expansion and activation of the renin-angiotensin system.30 
Other factors hypothesized to play a causative role include 
activation of the sympathetic nervous system by decreased 
blood flow to the kidneys or hypoxemia during sleep apnea 
events, alterations in endothelium derived vasoconstrictors 
and vasodilators, increased arterial stiffness, reactive oxy-
gen species (possibly secondary to vasoconstriction), renal 
ischemia, or recombinant human erythropoietin.30 Uncon-
trolled hypertension in patients with chronic kidney disease 
is common with an elevated serum creatinine being a strong 
predictor of resistant hypertension.1
Renal artery stenosis
While renal artery atherosclerotic disease is relatively 
common in hypertensive patients, what role obstructive 
lesions play in the elevated blood pressure of these patients 
is not known.1 In patients with resistant hypertension, renal 
artery atherosclerotic disease is a common secondary cause of 
hypertension, with a higher prevalence among older patients, 
smokers, patients with atherosclerotic vascular disease, and 
patients with unexplained renal insufficiency.1 Treatment of 
renal artery stenosis from atherosclerotic disease with surgical 
or endovascular revascularization has not been reliably shown 
to improve blood pressure control.1 In contrast, angioplasty 
of fibromuscular disease causing renal artery stenosis (RAS) 
can be curative and is almost always beneficial.1 Renal artery 
disease is most commonly related to atherosclerotic plaques, 
fewer than 10% of lesions being fibromuscular.1
Pheochromocytoma
While rare, pheochromocytoma may be found in a small 
minority of patients with RH. Elevated blood pressure occurs Integrated Blood Pressure Control 2009:1 12
Frank and Sommerfeld Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
T
a
b
l
e
 
1
 
D
r
u
g
s
 
p
o
t
e
n
t
i
a
l
l
y
 
c
a
u
s
i
n
g
 
s
e
c
o
n
d
a
r
y
 
h
y
p
e
r
t
e
n
s
i
o
n
1
4
,
1
8
,
2
9
,
7
9
D
r
u
g
P
r
o
p
o
s
e
d
 
m
e
c
h
a
n
i
s
m
 
o
f
 
e
f
f
e
c
t
E
s
t
i
m
a
t
e
d
 
r
a
t
e
 
o
f
 
e
l
e
v
a
t
e
d
 
b
l
o
o
d
 
p
r
e
s
s
u
r
e
 
a
m
o
n
g
 
d
r
u
g
 
u
s
e
r
s
R
i
s
k
 
f
a
c
t
o
r
s
T
r
e
a
t
m
e
n
t
 
(
i
f
 
u
n
a
b
l
e
 
t
o
 
d
i
s
c
o
n
t
i
n
u
e
 
m
e
d
i
c
a
t
i
o
n
)
C
o
r
t
i
c
o
s
t
e
r
o
i
d
M
i
n
e
r
a
l
o
c
o
r
t
i
c
o
i
d
 
a
c
t
i
v
i
t
y
 
I
n
c
r
e
a
s
e
d
 
a
r
t
e
r
i
a
l
 
r
e
s
i
s
t
a
n
c
e
 
I
n
c
r
e
a
s
e
d
 
c
a
t
e
c
h
o
l
a
m
i
n
e
 
s
e
n
s
i
t
i
v
i
t
y
1
5
%
–
2
0
%
O
l
d
e
r
 
p
a
t
i
e
n
t
s
 
 
F
a
m
i
l
y
 
h
i
s
t
o
r
y
 
 
o
f
 
h
y
p
e
r
t
e
n
s
i
o
n
F
l
u
i
d
 
r
e
s
t
r
i
c
t
i
o
n
 
 
D
i
u
r
e
t
i
c
s
N
a
t
u
r
a
l
 
l
i
c
o
r
i
c
e
M
i
n
e
r
a
l
o
c
o
r
t
i
c
o
i
d
 
e
x
c
e
s
s
N
o
t
 
a
p
p
l
i
c
a
b
l
e
K
e
t
o
c
o
n
a
z
o
l
e
M
i
n
e
r
a
l
o
c
o
r
t
i
c
o
i
d
 
e
x
c
e
s
s
F
l
u
i
d
 
r
e
s
t
r
i
c
t
i
o
n
D
i
u
r
e
t
i
c
s
C
o
m
b
i
n
e
d
 
o
r
a
l
 
c
o
n
t
r
a
c
e
p
t
i
v
e
s
V
o
l
u
m
e
 
e
x
p
a
n
s
i
o
n
 
(
s
t
i
m
u
l
a
t
e
s
 
m
i
n
e
r
a
l
o
c
o
r
i
t
i
c
o
i
d
 
r
e
c
e
p
t
o
r
s
)
I
n
c
r
e
a
s
e
 
p
l
a
s
m
a
 
c
o
n
c
e
n
t
r
a
t
i
o
n
s
 
o
f
 
a
n
g
i
o
t
e
n
s
i
n
o
g
e
n
2
–
3
 
t
i
m
e
s
 
i
n
c
r
e
a
s
e
d
 
r
i
s
k
 
c
o
m
p
a
r
e
d
 
t
o
 
n
o
n
-
u
s
e
r
s
H
i
s
t
o
r
y
 
o
f
 
e
l
e
v
a
t
e
d
 
b
l
o
o
d
 
p
r
e
s
s
u
r
e
 
d
u
r
i
n
g
 
p
r
e
g
n
a
n
c
y
F
a
m
i
l
y
 
h
i
s
t
o
r
y
 
o
f
 
h
y
p
e
r
t
e
n
s
i
o
n
T
o
b
a
c
c
o
 
u
s
e
B
l
a
c
k
 
r
a
c
e
O
b
e
s
i
t
y
D
i
a
b
e
t
i
c
s
S
w
i
t
c
h
 
t
o
 
p
r
o
g
e
s
t
i
n
-
o
n
l
y
 
c
o
n
t
r
a
c
e
p
t
i
v
e
 
o
r
 
o
n
e
 
c
o
n
t
a
i
n
i
n
g
 
d
r
o
s
p
i
r
e
n
o
n
e
 
 
(
4
t
h
-
g
e
n
e
r
a
t
i
o
n
 
p
r
o
g
e
s
t
i
n
)
D
a
n
a
z
o
l
S
a
l
t
,
 
w
a
t
e
r
 
r
e
t
e
n
t
i
o
n
D
i
u
r
e
t
i
c
s
C
y
c
l
o
s
p
o
r
i
n
e
R
e
n
a
l
 
v
a
s
o
c
o
n
s
t
r
i
c
t
i
o
n
5
0
%
–
7
0
%
 
w
h
e
n
 
u
s
e
d
 
i
n
 
r
e
n
a
l
 
o
r
 
h
e
p
a
t
i
c
 
t
r
a
n
s
p
l
a
n
t
 
r
e
c
i
p
i
e
n
t
s
D
i
u
r
e
t
i
c
s
 
(
m
a
y
 
w
o
r
s
e
n
 
p
r
e
r
e
n
a
l
 
a
z
o
t
e
m
i
a
)
,
 
c
a
l
c
i
u
m
 
c
h
a
n
n
e
l
 
b
l
o
c
k
e
r
s
 
(
c
a
n
 
i
n
c
r
e
a
s
e
 
s
e
r
u
m
 
l
e
v
e
l
s
 
o
f
 
c
y
c
l
o
s
p
o
r
i
n
e
)
E
r
y
t
h
r
o
p
o
i
e
t
i
n
V
a
s
o
c
o
n
s
t
r
i
c
t
i
o
n
2
0
%
–
3
3
%
F
a
m
i
l
y
 
o
r
 
p
e
r
s
o
n
a
l
 
h
i
s
t
o
r
y
 
 
o
f
 
h
y
p
e
r
t
e
n
s
i
o
n
A
n
t
i
h
y
p
e
r
t
e
n
s
i
v
e
 
m
e
d
i
c
a
t
i
o
n
 
(
4
2
%
 
e
f
f
e
c
t
i
v
e
l
y
 
t
r
e
a
t
e
d
 
w
i
t
h
 
m
o
n
o
t
h
e
r
a
p
y
)
H
e
m
o
d
i
a
l
y
s
i
s
 
p
a
t
i
e
n
t
s
 
–
 
fl
u
i
d
 
r
e
m
o
v
a
l
,
 
p
h
l
e
b
o
t
o
m
y
 
o
f
 
5
0
0
 
m
L
N
S
A
I
D
s
S
a
l
t
,
 
w
a
t
e
r
 
r
e
t
e
n
t
i
o
n
I
n
c
r
e
a
s
e
d
 
s
y
m
p
a
t
h
e
t
i
c
 
a
c
t
i
v
a
t
i
o
n
L
o
s
s
 
o
f
 
r
e
n
a
l
 
v
a
s
o
d
i
l
a
t
i
o
n
2
1
%
–
3
5
%
 
r
e
l
a
t
i
v
e
 
r
i
s
k
 
i
n
c
r
e
a
s
e
I
b
u
p
r
o
f
e
n
,
 
p
i
r
o
x
i
c
a
m
,
 
n
a
p
r
o
x
e
n
 
=
 
h
i
g
h
e
s
t
 
r
i
s
k
S
u
l
i
n
d
a
c
,
 
a
s
p
i
r
i
n
 
=
 
l
o
w
e
s
t
 
r
i
s
k
A
n
t
i
h
y
p
e
r
t
e
n
s
i
v
e
 
e
f
f
e
c
t
s
 
o
f
 
a
l
l
 
c
l
a
s
s
e
s
 
o
f
 
m
e
d
i
c
a
t
i
o
n
 
a
f
f
e
c
t
e
d
 
b
y
 
N
S
A
I
D
s
 
e
x
c
e
p
t
 
f
o
r
 
c
a
l
c
i
u
m
 
c
h
a
n
n
e
l
 
b
l
o
c
k
e
r
s
S
y
m
p
a
t
h
o
m
i
m
e
t
i
c
 
a
g
e
n
t
s
 
N
a
s
a
l
 
s
p
r
a
y
s
 
 
O
r
a
l
 
d
e
c
o
n
g
e
s
t
a
n
t
s
 
 
A
p
p
e
t
i
t
e
 
s
u
p
p
r
e
s
s
a
n
t
s
 
E
y
e
 
d
r
o
p
s
 
c
o
n
t
a
i
n
i
n
g
 
e
p
i
n
e
p
h
r
i
n
e
A
l
p
h
a
-
a
d
r
e
n
e
r
g
i
c
 
a
g
o
n
i
s
t
s
P
r
o
m
o
t
e
s
 
n
o
r
e
p
i
n
e
p
h
r
i
n
e
 
r
e
l
e
a
s
e
A
v
o
i
d
 
β
-
b
l
o
c
k
e
r
s
 
(
c
a
n
 
c
a
u
s
e
 
u
n
o
p
p
o
s
e
d
 
a
l
p
h
a
-
a
d
r
e
n
e
r
g
i
c
 
v
a
s
o
c
o
n
s
t
r
i
c
t
i
o
n
)
A
n
t
i
h
y
p
e
r
t
e
n
s
i
v
e
 
a
g
e
n
t
s
 
m
a
y
 
b
e
 
u
s
e
dIntegrated Blood Pressure Control 2009:1 13
Resistant hypertension Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
A
l
c
o
h
o
l
I
m
p
a
i
r
e
d
 
b
a
r
o
r
e
fl
e
x
S
y
m
p
a
t
h
e
t
i
c
 
a
c
t
i
v
a
t
i
o
n
I
n
c
r
e
a
s
e
d
 
i
n
t
r
a
c
e
l
l
u
l
a
r
 
c
a
l
c
i
u
m
C
o
r
t
i
s
o
l
 
e
x
c
e
s
s
 
 
S
o
d
i
u
m
 
m
e
t
a
b
o
l
i
s
m
 
a
b
n
o
r
m
a
l
i
t
i
e
s
5
0
%
 
i
n
c
r
e
a
s
e
d
 
r
i
s
k
 
w
i
t
h
 

4
 
g
l
a
s
s
e
s
 
p
e
r
 
d
a
y
L
i
m
i
t
 
t
o
 
1
 
o
u
n
c
e
 
o
f
 
4
0
%
 
e
t
h
a
n
o
l
 
f
o
r
 
m
e
n
 
o
r
 
0
.
5
 
o
u
n
c
e
 
f
o
r
 
w
o
m
e
n
 
d
a
i
l
y
C
o
c
a
i
n
e
S
y
m
p
a
t
h
e
t
i
c
 
a
c
t
i
v
a
t
i
o
n
A
l
p
h
a
-
a
d
r
e
n
e
r
g
i
c
 
r
e
c
e
p
t
o
r
 
a
n
t
a
g
o
n
i
s
t
s
D
i
r
e
c
t
 
v
a
s
o
d
i
l
a
t
o
r
s
C
a
l
c
i
u
m
 
c
h
a
n
n
e
l
 
b
l
o
c
k
e
r
s
C
o
m
b
i
n
e
d
 
a
l
p
h
a
/
b
e
t
a
 
b
l
o
c
k
e
r
s
A
m
p
h
e
t
a
m
i
n
e
s
S
y
m
p
a
t
h
e
t
i
c
 
a
c
t
i
v
a
t
i
o
n
N
o
 
d
a
t
a
A
n
t
i
d
e
p
r
e
s
s
a
n
t
s
I
n
c
r
e
a
s
e
d
 
n
o
r
e
p
h
i
n
e
p
h
r
i
n
e
 
(
M
A
O
 
i
n
h
i
b
i
t
o
r
s
)
I
n
g
e
s
t
i
o
n
 
o
f
 
t
y
r
a
m
i
n
e
 
c
o
n
t
a
i
n
i
n
g
 
f
o
o
d
s
 
w
h
i
l
e
 
t
a
k
i
n
g
 
M
A
O
I
α
-
 
a
n
d
 
c
o
m
b
i
n
e
d
 
 
α
-
/
β
-
b
l
o
c
k
e
r
s
 
(
f
o
r
 
M
A
O
I
-
i
n
d
u
c
e
d
 
h
y
p
e
r
t
e
n
s
i
o
n
)
D
i
u
r
e
t
i
c
s
 
o
r
 
d
i
r
e
c
t
 
a
c
t
i
n
g
 
v
a
s
o
d
i
l
a
t
o
r
s
R
e
n
i
n
 
s
t
i
m
u
l
a
t
i
o
n
A
v
o
i
d
 
v
o
l
u
m
e
 
d
e
p
l
e
t
i
o
n
C
l
o
n
i
d
i
n
e
P
e
r
i
p
h
e
r
a
l
 
v
a
s
o
c
o
n
s
t
r
i
c
t
i
o
n
A
b
r
u
p
t
 
d
i
s
c
o
n
t
i
n
u
a
t
i
o
n
 
c
a
n
 
c
a
u
s
e
 
r
e
b
o
u
n
d
 
c
a
t
e
c
h
o
l
a
m
i
n
e
 
p
r
o
d
u
c
t
i
o
n
C
o
n
c
u
r
r
e
n
t
 
u
s
e
 
o
f
 
c
l
o
n
i
d
i
n
e
 
a
n
d
 
β
-
b
l
o
c
k
e
r
 
i
n
c
r
e
a
s
e
s
 
r
i
s
k
 
f
o
r
 
r
e
b
o
u
n
d
 
h
y
p
e
r
t
e
n
s
i
o
n
 
u
p
o
n
 
d
i
s
c
o
n
t
i
n
u
a
t
i
o
n
T
a
p
e
r
 
d
o
s
e
 
w
h
e
n
 
d
i
s
c
o
n
t
i
n
u
i
n
g
M
e
t
h
y
l
d
o
p
a
I
n
i
t
i
a
l
 
e
x
a
c
e
r
b
a
t
i
o
n
 
o
f
 
h
y
p
e
r
t
e
n
s
i
o
n
W
i
l
l
 
r
e
s
o
l
v
e
 
w
i
t
h
 
c
o
n
t
i
n
u
e
d
 
a
d
m
i
n
i
s
t
r
a
t
i
o
n
 
(
i
n
i
t
i
a
l
 
e
f
f
e
c
t
 
o
n
l
y
)
β
-
b
l
o
c
k
e
r
D
i
s
c
o
n
t
i
n
u
a
t
i
o
n
 
c
a
n
 
c
a
u
s
e
 
u
p
r
e
g
u
l
a
t
i
o
n
 
o
f
 
β
 
r
e
c
e
p
t
o
r
s
T
a
p
e
r
 
d
o
s
e
 
w
h
e
n
 
d
i
s
c
o
n
t
i
n
u
i
n
g
K
e
t
a
m
i
n
e
I
n
c
r
e
a
s
e
s
 
s
y
s
t
e
m
i
c
v
a
s
c
u
l
a
r
 
r
e
s
i
s
t
a
n
c
e
α
-
b
l
o
c
k
e
r
s
,
 
c
l
o
n
i
d
i
n
e
D
e
s
fl
u
r
a
n
e
S
y
m
p
a
t
h
o
m
i
m
e
t
i
c
A
l
p
h
a
 
b
l
o
c
k
e
r
s
,
 
c
l
o
n
i
d
i
n
e
,
 
c
o
m
b
i
n
e
d
 
α
-
 
α
-
/
β
-
b
l
o
c
k
e
r
s
E
r
g
o
t
 
a
l
k
a
l
o
i
d
s
B
r
o
m
o
c
r
i
p
t
i
n
e
V
a
s
o
c
o
n
s
t
r
i
c
t
i
o
n
H
i
s
t
o
r
y
 
o
f
 
g
e
s
t
a
t
i
o
n
a
l
 
h
y
p
e
r
t
e
n
s
i
o
n
S
i
b
u
t
r
a
m
i
n
e
A
f
f
e
c
t
s
 
v
a
s
c
u
l
a
r
 
a
f
f
e
r
e
n
t
 
n
e
r
v
e
s
A
n
t
i
-
e
m
e
t
i
c
s
M
e
t
o
c
l
o
p
r
a
m
i
d
e
 
P
r
o
c
h
l
o
r
p
e
r
a
z
i
n
e
T
r
e
a
t
e
d
 
w
i
t
h
 
c
i
s
p
l
a
s
t
i
n
 
 
C
o
-
e
x
i
s
t
i
n
g
 
p
h
e
o
c
h
r
o
m
o
c
y
t
o
m
aIntegrated Blood Pressure Control 2009:1 14
Frank and Sommerfeld Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
in 95% of patients with pheochromocytoma, although only 
about half of patients have persistently elevated blood pres-
sure.1 Pheochromocytoma should be considered in a patient 
with resistant hypertension who experiences headaches, 
palpitations, and sweating.1
Cushing’s syndrome
Elevated blood pressure is common in patients with 
Cushing’s syndrome with a prevalence of resistant hyper-
tension that may be similar to the general population of 
patients with hypertension (about 1 in 5).1 The pathophysi-
ologic mechanism of blood pressure elevation in Cushing’s 
syndrome can result in most antihypertensive agents being 
ineffective in lowering blood pressure.1 Mineralocorticoid 
receptor antagonists are particularly effective antihyperten-
sive agents in patients with Cushing’s syndrome since blood 
pressure elevation results from cortisol-mediated activation 
of the mineralocorticoid receptors.1 However, other factors 
can play a role in blood pressure elevation including OSA 
and insulin resistance.1
Patient evaluation
Resistant hypertension is not uncommonly linked to other 
medical conditions, and patient evaluation should focus on 
historical features which may suggest related conditions (see 
Table 2). Obstructive sleep apnea should be considered in 
any patient with daytime somnolence, snoring, and witnessed 
apnea. RAS should be considered in patients with signs or 
symptoms of peripheral or coronary artery disease. Pheochro-
mocytoma should be considered when labile hypertension is 
accompanied by palpitations and diaphoresis.
Nonadherence to prescribed antihypertensive medications 
is common with reported prevalence at 40% to 60%.1,18 
Medication nonadherence is more common in chronic, 
asymptomatic diseases and for treatment that lasts longer 
than 6 months, making non-adherence in the treatment of 
hypertension a particular problem.12 Therefore, patients 
should be assessed for medication adherence at each visit and 
particularly with apparent resistant hypertension. Clinicians 
should be aware of factors which may increase the risk of 
patient nonadherence such as medication side effects, cost, 
and dosing inconvenience of prescribed medications1 as 
well as poor patient understanding of medication purpose 
and use or the presence of organic brain dysfunction impair-
ing the patient’s ability to take medications as prescribed.18 
Additional information solicited from patients may include 
whether the patient understands which medications are pre-
scribed for hypertension, how medications are organized, 
stored, and administered at home, and whether medications 
are being transferred from old prescription bottles or shared 
with other family members. Family members are another 
potential source of information and may be particularly good 
resources when assessing medication adherence in older or 
disabled patients who may be more dependent on family 
assistance in securing and administering medications.1 Clini-
cians can promote medication adherence through patient edu-
cation, selecting once-daily dosing regimens when possible, 
avoiding drug interactions, and providing reminders and 
positive feedback on improved blood pressure values.19
Assessing adherence can be challenging but is a neces-
sary component in the evaluation of a patient with apparent 
resistant hypertension. Use of an electronic monitoring system 
improves detection of patient’s non-adherence with prescribed 
medications and is superior to pill counting or physician esti-
mates of adherence.31 Several issues regarding adherence to 
prescription medication regimens should be considered. The 
first is that adherence is a dynamic process – varying over 
time and improving right before a scheduled office visit.31 
Additionally, the type of antihypertensive medication plays 
a role with angiotensin receptor blockers (ARBs) being asso-
ciated with the highest likelihood of continued adherence.31 
Finally, electronic monitoring of adherence, beyond improved 
identification of poor adherence, has been demonstrated to 
improve blood pressure control.31 If questions remain about 
medication adherence, consideration should be given to a 
short term hospitalization for closer observation.19
Physical examination
Establishing the diagnosis of resistant hypertension starts 
by properly evaluating blood pressure measurement and 
excluding white coat hypertension.1 Clinic blood pressure 
measurement can be falsely elevated due to a number of 
factors including room temperature, recent patient exercise, 
nicotine, alcohol or other recent substance use by the patient, 
incorrect arm position of the patient, talking by the clinician 
or patient and inability of the clinician to hear the Korotkoff 
sounds.32 Clinic measurement of blood pressure should occur 
after the patient has been sitting for at least 5 minutes. The 
patient should be seated with both back and arm supported 
and legs uncrossed. The blood pressure cuff should not be 
placed over any clothing and clothing should be removed to 
avoid a constricting effect on the upper arm.32 The patient’s 
arm should be at heart level with a cuff that encircles 
at least 80% of the arm circumference.32 Clinicians can 
demonstrate two types of digit bias – both for a terminal zero 
(ie, 120 instead of 122) and for a reading indicating that goal Integrated Blood Pressure Control 2009:1 15
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has been achieved.32 It is recommended that 2 measurements 
be taken at least 1 minute apart and averaged to obtain the 
blood pressure reading.32
The physical examination of a patient with suspected 
resistant hypertension should focus on identification of both 
micro- and macrovascular complications.1 The presence 
of end-organ damage supports a history of uncontrolled 
hypertension.1 Evaluation for end-organ damage includes 
a fundoscopic examination looking for retinopathy and a 
cardiovascular examination looking for bruits and displace-
ment of the PMI indicating left-ventricular hypertrophy.1 
Additional historical and physical exam findings that may 
indicate secondary causes of hypertension should be sought 
(see Table 2).
Laboratory evaluation
Laboratory evaluation of a patient with known or suspected 
resistant hypertension includes a hematocrit, basic metabolic 
panel, a urinalysis including testing for microalbumin, lipids, 
glucose, uric acid, thyroid stimulating hormone (as thyroid 
disease is associated with hypertension), and a screen for pri-
mary aldosteronism (see below).1,3,12 Serum creatinine should 
not be relied upon to identify chronic kidney disease and a 
glomerular filtration rate using the Modification of Diet in 
Renal Disease equation should be calculated in patients with 
resistant hypertension.12,29 If pheochromocytoma is suspected, 
a urine or plasma test for fractionated free metanephrines 
(ie, metanephrine and normetanephrine) is indicated. The 
plasma test has a reported 99% to 100% sensitivity and an 
89% to 97.6% specificity.1,33 Testing for microalbuminuria is 
important for identification of end-organ damage that provides 
prognostic information on cardiovascular risk but also because 
it may affect choice of antihypertensive medications.18
Screening for primary aldosteronism can be done with 
plasma renin and serum aldosterone ratio measurement (which 
has a high sensitivity but low specificity) and confirmed with 
sodium loading or fludrocortisone suppression testing.12,23 
While measurement of serum aldosterone – plasma renin ratio 
has a high negative predictive value, it may be falsely posi-
tive up to 50% of the time.23 Confirmatory testing of primary 
aldosteronism can be done with infusion of 2 L of normal 
saline over 4 hours followed by measurement of plasma aldo-
sterone. Failure of the saline infusion to suppress aldosterone 
to less than 5 to 10 ng/dL indicates primary aldosteronism.28 
Alternatively, 24-hour urine excretion of aldosterone can be 
measured as an outpatient during dietary sodium loading.28 
Hypokalemia is not a reliable indicator of PA as it may be 
normal early in the disease course.23,24
Diagnostic testing
Electrocardiography (ECG) is indicated in patients with 
resistant hypertension to evaluate for left ventricular hyperten-
sion (LVH).3,12 LVH can both support the diagnosis of resistant 
hypertension, as end-organ damage is more commonly found 
in patients with true resistant hypertension, as well as identify 
patients at increased cardiovascular risk. Echocardiography is 
more sensitive in detecting LVH but is also more expensive. 
It may be considered in patients in whom a strong suspicion 
exists for LVH and may be particularly useful in men older 
than 50 years for whom the pretest probability is higher.34
Renal artery stenosis due to atherosclerosis is common 
in older patients. Screening for RAS can be done using mag-
netic resonance angiography (MRA), computer tomographic 
angiography (CTA), Doppler ultrasonography, or angiotensin-
converting enzyme (ACE) inhibitor renography.12,35 MRA or 
Doppler ultrasonography are preferred in patients with renal 
impairment.35
Treatment
Treatment of resistant hypertension focuses on several 
components. These include maximizing therapeutic lifestyle 
changes, withdrawing any medications or substances which 
may contribute to elevated blood pressure, treatment of underly-
ing conditions (such as obstructive sleep apnea) (see Table 3), 
maximizing medication adherence, and focusing on pharmaco-
logic modalities likely to achieve target blood pressure.1
Nonpharmacologic treatment focuses on weight loss, 
dietary salt restriction (100 mEq/24 hours), decreased alco-
hol ingestion, increased physical activity, and ingestion of a 
high-fiber, low-fat diet rich in fruits and vegetables.1,36 Weight 
loss has not been specifically studied in patients with RH but 
has been found to reduce both systolic and diastolic blood 
pressure in hypertensive patients.1,37 A low salt diet may be 
more likely to benefit patients who are at increased likelihood 
of salt-sensitivity, including older patients, African-American 
patients, and those with chronic kidney disease.37
The timing of medication administration can affect blood 
pressure control. In patients with uncontrolled hypertension 
on 3 or more antihypertensive medications all taken on awak-
ening, switching one medication to bedtime administration 
resulted in significantly reduced 24-hour systolic and diastolic 
blood pressures, with 21.7% to 37% of those who changed 
one medication to bedtime dosing having their blood pressures 
subsequently controlled.38,39 Also shown was a reduction in the 
nocturnal nondipping pattern (10% reduction in nocturnal 
versus daytime blood pressures), which may be of relevance 
given the evidence showing that nocturnal blood pressure Integrated Blood Pressure Control 2009:1 16
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readings are a better predictor of cardiovascular complications 
than 24-hour or daytime blood pressure readings.40–43
In a small study of 44 Brazilian patients, adding a pharma-
cist to the health care delivery team demonstrated improve-
ment in blood pressure reduction, although half of the patients 
still had not reached their blood pressure goal, and showed 
improvement in one measure of social functioning.44 Pharma-
cist interventions included patient education, blood pressure 
measurement, and assessing adherence. Patient medication 
adherence increased from 63.3% to 95.5% at study end.
Pharmacologic treatment
Pharmacologic treatment should concentrate on use of an 
appropriate diuretic with a thiazide diuretic for most patients 
and a loop diuretic for those with a decreased glomerular 
filtration rate.10 One recommended treatment foundation 
is a combination of a thiazide diuretic with a long-acting 
calcium channel blocker (CCB) and an ACE inhibitor or 
an angiotensin receptor blocker.10 Chlorthalidone may be 
preferred over hydrochlorothiazide, particularly in patients 
with resistant hypertension (see Table 4).24 Additional 
fourth-, fifth-, and sixth-line agents can be added based on 
individual patient characteristics with consideration given 
to treatment recommendations outlined by JNC VII.36 Other 
agents which should be considered include a mineralocor-
ticoid antagonist, a combination alpha-beta blocker over a 
pure beta blocker, or direct vasodilating agents (hydralazine 
or minoxidil).10
Table 2 History and physical examination elements suggestive of secondary causes of hypertension1,3,14,19,29,33,70
Disease Historical findings Physical exam findings Laboratory or diagnostic study 
findings
Chronic kidney disease Comorbidities potentially 
causing kidney damage 
Nocturia
edema Decreased creatinine clearance, 
abnormal urinalysis (proteinuria, 
hematuria, pyuria), abnormal renal 
ultrasonography, MRA, CTA, or ACE 
inhibitor renal scan
Coarctation of the aorta Differential in brachial  
and femoral pulses,  
systolic bruit, systolic  
heart murmur
Echocardiography findings consistent 
with coarctation
Cushing’s syndrome Muscle weakness or fatigue, 
emotional disturbances, 
decreased libido, amenorrhea
Moon facies,  
central adiposity,  
abdominal striae,  
interscapular fat deposition, 
fluid retention
Elevated plasma cortisol level after 
dexamethasone administration
Obstructive sleep apnea Snoring, witnessed 
apnea, excessive daytime 
somnolence, male gender
Obese, redundant pharyngeal 
soft, tissues, large shirt collar 
size
Abnormal sleep study
Pheochromocytoma Episodic hypertension with 
diaphoresis, palpitations, or 
headache, positive family 
history, labile blood  
pressure
Café-au-lait spots or 
neurofibromas,  
suprarenal or midline 
abdominal mass
Elevated 24-hour urine metanephrine 
to creatinine ratio or plasma free 
metanephrine (90%–100% sensitive 
and 89%–97.6% specific)
Primary aldosteronism Muscle cramps  
Weakness  
Polyuria  
Polydipsia (less common)
Elevated aldosterone/renin ratio, 
elevated serum aldosterone with salt 
loading, hypokalemia (usually a later 
finding), abnormal CT scan showing 
adrenal adenoma
Renal artery stenosis Young female (fibromuscular 
disease), older age, smoker, 
history of atherosclerotic 
disease, renal insufficiency, 
absence of obesity, history 
of flash pulmonary edema 
(atheroscleric lesion)
Renal or carotid artery bruit Impaired renal function after addition 
of or increased dose of ACE inhibitor 
or angiotensin-receptor blocker
Abbreviations: MRA, magnetic resonance angiography; CTA, computer tomographic angiography;  ACE, angiotensin-converting enzyme.Integrated Blood Pressure Control 2009:1 17
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Diuretics
Diuretic treatment is an important component of pharmacologic 
management of resistant hypertension since hypervolemia is 
common in patients with RH.19,24,45 Hypervolemia can result 
from excess sodium ingestion, progressive renal damage, 
fluid retention from blood pressure reduction, and underuse of 
diuretic treatment.18 Diuretics are underused in the treatment 
of hypetension1,37,46 for a variety of reasons, including concern 
regarding metabolic side effects and misconceptions about 
maximum dosages.3,36 Addition of, increasing the dose of, 
or changing the class of diuretic is a recommended first step 
in the treatment approach to RH24 and may improve blood 
pressure in up to 50% of patients.19,46
Hydrochlorothiazide is used more commonly in clinical 
practice13 than chlorthalidone, a thiazide-like diuretic, prob-
ably because of increased ease of use with hydrochlorothiazide 
having more formulations available and being available in 
fixed-dose combination pills.37,45,46 While chlorthalidone and 
hydrochlorothiazide have not been compared for efficacy or 
tolerability in head-to-head trials, the greater clinical trial evi-
dence is found for use of chlorthalidone for the prevention of 
cardiovascular morbidity and mortality.45 Hydrochlorothiazide 
is commonly used in doses up to 25 mg daily, however doses 
up to 50 mg daily can provide improved control.36 Despite 
similar office blood pressure readings, chlorthalidone provides 
more effective 24-hour blood pressure control than hydro-
chlorothiazide.47 This may be explained by their differences 
in duration of action: 16 to 24 hours for hydrochlorothiazide 
and 48 to 72 hours for chlorthalidone.48 Chlorthalidone is 
approximately twice as potent as hydrochlorothiazide; eg, 
25 mg of hydrochlorothiazide is roughly equipotent to 12.5 mg 
of chlorthalidone.47,48 Hypokalemia has been raised as a 
concern with chlorthalidone. One cross-over study found no 
difference in the incidence of hypokalemia between equipo-
tent dosages of hydrochlorothiazide and chlorthalidone,47 but 
overall the evidence is mixed about the incidence of hypo-
kalemia between the two agents.13,46 Given its better 24-hour 
blood pressure control, chlorthalidone up to 25 mg daily is 
recommended preferentially in resistant hypertension.1,10,45,46,49 
Caution should be used with thiazide diuretics in patients with 
a history of significant hyponatremia, hypokalemia or gout.36 
Sodium and potassium levels should be monitored regardless 
of choice of diuretic.45
For patients with decreased renal function (creatinine 
clearance 30 to 50 mL/min), thiazide diuretics are not as 
effective.1,3 Therefore, for these patients, loop diuretics are 
preferred. If short-acting loop diuretics such as furosemide or 
bumetanide are used, they must be dosed at least twice daily 
for effective blood pressure control.3,38,50
Aldosterone antagonists
Spironolactone, an aldosterone-antagonist, is an important tool 
in the pharmacologic management of resistant hypertension. 
As mentioned above, aldosterone excess is common in patients 
with resistant hypertension and also appears to be related to obe-
sity and obstructive sleep apnea, two prevalent co-morbidities 
among patients with resistant hypertension. Therefore, it is 
logical that aldosterone blockade would play a role in the treat-
ment of resistant hypertension. Studies demonstrate a benefit 
of spironolactone treatment in patients both with and without 
primary aldosteronism.28
The addition of low dose spironolactone (range of 12.5 to 
50 mg daily) in the setting of refractory or resistant hyperten-
sion lowered systolic blood pressure by 21.7 to 28 mmHg 
Table 3 Treatment of secondary causes of hypertension3,19,29
Disease Treatment recommendations
Chronic kidney disease Diuretic treatment (loop diuretic preferred with decreased glomerular filtration rate), 
ACE inhibitors to decrease proteinuria and slow progression of diabetic nephropathy, 
calcium channel blocker
Coarctation of the aorta Surgery or balloon angioplasty
Cushing’s disease Surgical resection of pituitary adenoma, pituitary irradiation
Obstructive sleep apnea CPAP, weight loss, consider aldosterone antagonists
Pheochromocytoma Surgery, α- and/or β-blockers
Primary aldosteronism Surgical removal of adrenal adenoma, aldosterone antagonists for adrenal hyperplasia, 
non-surgical candidates
Renal artery stenosis – atherosclerotic disease Controversial, ongoing trial (CORAL) evaluating medical treatment vs stent placement 
Stent preferred over balloon angioplasty
Renal artery stenosis – fibromuscular disease Balloon angioplasty
Abbreviations: CPAP, continuous positive airway pressure; ACE, angiotensin-converting enzyme.Integrated Blood Pressure Control 2009:1 18
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and diastolic blood pressure by 8.5 to 13 mmHg. This was 
achieved regardless of presence of primary aldosteronism. In 
addition, pretreatment serum aldosterone levels, aldosterone 
excretion, and aldosterone/renin ratio did not predict blood 
pressure response to spironolactone.51–55 This has lead to 
increased recommendation for spironolactone in resistant 
hypertension,1,9,10,28,51–55 even as a fourth-line agent.13,44
Dosing is usually initiated at 25 mg daily, though 
12.5 mg daily may be more appropriate in patients with 
diabetes mellitus, chronic kidney disease, and in the elderly. 
Spironolactone can be initiated simultaneously with a 
thiazide diuretic for the dual benefit of blood pressure control 
and potassium balance.13,28,56 Those on ACE inhibitors or 
ARBs are at increased risk of hyperkalemia. If patients are 
taking supplemental potassium, this should be discontinued 
(or reduced if taking significant quantities) on initiation of 
spironolactone. Potassium levels and renal function should be 
assessed in 4 weeks after initiation, except for the high risk 
groups mentioned previously, where assessment sooner may 
be warranted. Titration should be at 4- to 6-week intervals, 
with repeat assessment of potassium and renal function 
as above. Mild hyperkalemia can usually be managed 
with a reduction in dose, while with serum potassium 
levels  5.5 mEq/L, spironolactone should be discontinued, 
possibly resuming at a lower dose once potassium levels have 
normalized. Dosages up to 50 mg daily have been studied in 
resistant hypertension; higher dosages may be warranted in 
those with confirmed primary aldosteronism.54,57,58
In addition to hyperkalemia and renal insufficiency, breast 
tenderness is a commonly cited adverse reaction to spironolac-
tone. This effect is dose dependent and occurs in approximately 
10% of men taking 25 mg daily.28,54 In these patients, therapy can 
be discontinued, then restarted at a lower dose once the tender-
ness has resolved. Other adverse reactions include gynecomas-
tia, menstrual irregularities, and erectile dysfunction.54,58
Amiloride, an indirect aldosterone antagonist that is better 
tolerated due to its lack of antiandrogenic action, has not been 
studied in resistant hypertension as much as spironolactone 
has. One small study found that in patients with uncon-
trolled hypertension, the addition of 2.5 mg of amiloride 
daily decreased systolic blood pressure by 31 mmHg and 
diastolic by 15 mmHg.59 However, an audit of the use of 
10 mg amiloride showed half the blood pressure reduction 
of spironolactone 25 mg daily.60 Until more studies are com-
pleted, spironolactone should be used preferentially, unless 
the patient is unable to tolerate spironolactone. If amiloride 
is used, monitoring of potassium and renal function should 
be performed as mentioned above for spironolactone.
Eplerenone, a more selective aldosterone antagonist, is 
effective in the treatment of hypertension but has not been 
well studied in RH.10,13 It may be considered in patients intol-
erant of spironolactone, particularly those with sex-hormone 
related side effects (breast tenderness, gynecomastia, erectile 
dysfunction, and menstrual irregularities).24
Renin-angiotensin blockade
ACE inhibitors also have a long history of use for hyper-
tension and are particularly recommended in patients with 
diabetes mellitus, heart failure, post-myocardial infarction, 
chronic kidney disease, high coronary disease risk, and 
recurrent stroke prevention.36,61 ARBs are an alternative for 
patients intolerant of ACE inhibitors. While studies looking 
at the combination of ACE inhibitors and ARBs in treat-
ing hypertension have shown improvement compared with 
monotherapy, most of these studies have not used maximum 
dosing of the monotherapy agent.1 In addition, combination 
ACE inhibitor/ARB therapy is not as effective as adding a 
diuretic or CCB to an ARB.62 Recent studies have indicated 
the possibility of increased adverse renal outcomes with 
dual ACE inhibitor and ARB treatment while not improv-
ing other clinical outcomes.63,64 Thus, dual ACE inhibitor 
and ARB therapy is not currently recommended for most 
patients.1,50,65 Dosage of an ACE inhibitor or ARB may be 
increased to the maximum recommended dosage as long as 
the serum creatinine does not increase more than 35% above 
baseline and hyperkalemia does not develop.36 Some patients 
will develop a mild (0.4 to 0.6 mmol/dL) increase in serum 
potassium levels that is self limiting.66
Calcium channel blockers
CCBs are further divided into dihydropyridine CCBs 
(amlodipine, felodipine, nicardipine, nifedipine, nisoldipine) 
and nondihydropyridine CCBs (diltiazem and verapamil). 
Both are recommended as possible initial drug therapy for 
hypertension by JNC VII.36 Dihydropyridine CCBs bind with 
greater affinity to blood vessel receptors compared with non-
dihydropyridine CCBs which have equal affinity for blood 
vessel and cardiac receptors.67 In doses used in clinical prac-
tice, nondihydropyridine CCBs can cause decreased cardiac 
conduction and myocardial contractility.67 CCBs have been 
recommended as a component of a three-medication regimen 
which includes a thiazide diuretic and either an ACE inhibitor 
or an ARB, based partly on their complementary mechanism 
of action.1,50 Common side effects of CCBs include constipa-
tion and edema, the later usually not responsive to diuretic 
therapy.46Integrated Blood Pressure Control 2009:1 20
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β-blockers and α-blockers
β-blockers have long been used for hypertension and are 
particularly recommended for patients with increased cardio-
vascular disease risk, heart failure, post-myocardial infarction, 
and diabetes mellitus.36 While masking of hypoglycemia has 
been a concern of using β-blockers in the setting of diabetes 
mellitus, a review found no evidence of β1-selective blockers 
masking hypoglycemia, prolonging hypoglycemia, or adversely 
affecting glucose metabolism.68 β-blockers do have a disadvan-
tage of reflexively causing increased peripheral edema. This 
has lead some experts to recommend α-blockers in conjunction 
with β-blockade, though not as first line therapy.1,3,13,49 This is in 
part due to the significant increase in cardiovascular events and 
hospitalization in doxazosin compared with chlorthalidone seen 
in the ALLHAT study that resulted in the early termination of 
the doxazosin arm.69 That said, α-blockers may be more a more 
logical choice in patients with lower urinary tract symptoms. 
Particular care should be taken to monitor for orthostatic hypo-
tension with the use of α-blockers.
Combination strategies
Thiazide diuretics can be safely and effectively combined 
with almost all classes of antihypertensive medications.24 
A three-drug regimen containing a thiazide diuretic, a 
calcium-channel blocker, and an ACE inhibitor or ARB 
is advocated.24,28 While this triple therapy has not been 
widely studied, thiazide diuretics in combination with 
most classes of medications have proven more effective in 
blood pressure lowering than combinations not containing 
a diuretic.24
No specific combination regimen has been shown supe-
rior to others in the treatment of resistant hypertension. 
However, it is logical to use certain principles in guiding 
combination treatment. Patients should be treated with 
antihypertensive agents per compelling indications.36 Aside 
from these recommendations, patients can be assessed for 
the presumed underlying mechanism of hypertension (renin-
based, aldosterone-based, hemodynamic/volume) in order 
to guide therapy recognizing that physician assessment 
of the underlying cause is both complex and difficult.14,70 
What may be more practical is to assess the patient’s cur-
rent regimen and treatment response, as most patients with 
resistant hypertension are already on a number of different 
agents. Patients with an incomplete response to a certain 
agent may benefit from an increased dose of that agent or 
addition of a second agent with a complimentary mechanism 
of action.13 While substitution of one agent for another is a 
potential strategy, add-on therapy is generally preferred,13 
since complimentary mechanisms of action will improve 
overall efficacy of the regimen.
When adding on medications to combinations already 
containing a diuretic, CCB, ACE inhibitor or ARB, con-
sideration should be given to combined α-β blockers over 
pure β-blockers3,71 and either centrally acting medications 
(clonidine, methyldopa) or direct vasodilators (minoxidil, 
hydralazine) although use of these latter two classes is 
limited by tolerability and frequent dosing.24 Combined α-β 
blockers, either through use of a single agent (carvedilol, 
labetalol) or two agents may offer benefits particularly in 
patients who have failed to achieve target blood pressure on 
a diuretic/ACE-inhibitor combination.71 As a result of the 
potent vasodilation produced by direct acting vasodilators, 
β-blockers and loop diuretics are usually necessary to over-
come the reflex tachycardia and fluid retention, respectively. 
If patients are requiring these medications to control their 
blood pressure, hypertension specialists should likely be 
involved.1,13,49,72
Fixed-dose combination pills have been shown to increase 
adherence versus equivalent therapy with single-agent 
medications;73 however few studies have been performed 
comparing the efficacy of combination pills versus using 
combined monotherapy agents from each class included in 
the fixed-dose combination pill.74 Unfortunately, most fixed 
dose combination pills do not provide maximum dosages 
of included agents,74 though many monotherapy agents will 
require multiple pills to reach maximum dosages as well.
Other agents
Endothelin receptor antagonists are a new family of antihy-
pertensive medications that are currently being evaluated. 
Darusentan, a selective endothelin receptor antagonist cur-
rently under investigation and not yet available for clinical 
use, demonstrated sustained dose-dependent lowering of blood 
pressure in phase II studies.75 Darusentan is an antagonist selec-
tive for type A endothelin receptors, activation of which causes 
vasoconstriction and proliferation of vascular smooth muscle.75 
Medication interactions, though not tested, are theorized to be 
low based on its elimination profile.76 Doses of up to 300 mg 
daily of darusentan were associated with significant reductions 
in both systolic and diastolic blood pressures that persisted 
over 24 hours, as measured by ambulatory blood pressure 
monitoring. However, there was no statistically significant 
difference between the groups in percent of patients achiev-
ing blood pressure goals (although there was a trend favoring 
darusentan).75 Headache and edema were the most common 
intervention related side effects.75 Potential adverse events of Integrated Blood Pressure Control 2009:1 21
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endothelin receptor antagonists (teratogenicity, hepatotoxicity) 
limit their use as first-line agents, but this study indicates 
a possible role for darusentan in the treatment of resistant 
hypertension. It should be noted that significant hepatotoxicity 
was not observed in this 10-week trial study.75
A double blind placebo-controlled randomized trial of 
obese patients with uncontrolled hypertension despite treat-
ment found that orlistat, compared with placebo, resulted in 
decreased diastolic blood pressures (−11.4 mmHg compared 
with −9.2 mmHg) and improved rates of achieving diastolic 
blood pressure goals (67% compared to 53%).77 The group 
treated with orlistat did achieve greater weight loss than the 
placebo group. The study was limited by high drop out rates 
in both the orlistat and placebo arm.
For patients who are truly resistant to antihypertensive 
medications and a thorough work-up for secondary causes has 
been completed, electrical carotid sinus baroreflex stimula-
tion implantable devices have been shown in feasibility trials 
to reduce systolic blood pressure by 22 to 24 mmHg.78
Conclusion
Resistant hypertension should be differentiated from uncon-
trolled hypertension due to medication nonadherence, under-
treatment, or pseudoresistance. True resistant hypertension can 
be diagnosed by taking a careful history, through confirmatory 
blood pressure measurement with 24-hour ambulatory blood 
pressure monitoring, and by detecting clues on examination 
that indicate the presence of end-organ damage. When resistant 
hypertension is diagnosed, it is important to consider secondary 
causes such as primary aldosteronism or obstructive sleep apnea 
that may be causing or contributing to elevated blood pressure 
readings. Treatment is focused on both nonpharmacologic 
(weight loss, exercise, limiting sodium intake) and pharmaco-
logic modalities. Additionally, identification of and treatment of 
secondary causes is essential. Pharmacologic treatment initially 
focuses on optimizing diuretic treatment and is followed by 
selection of patient specific combination strategies. Referral 
to a hypertension specialist is considered when pharmacologic 
treatment fails to achieve blood pressure goals.
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